{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:12:49Z","timestamp":1762506769060,"version":"build-2065373602"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>Chronic hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) genotype 1 historically has been the most difficult to treat <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype, and patients infected with this genotype had been previously treated with interferon\u2010based therapy. In recent years, however, treatment options for chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection have rapidly changed to an all\u2010oral regimen. Ledipasvir\u2013sofosbuvir is an oral fixed\u2010dose (ledipasvir 90 mg\u2013sofosbuvir 400 mg) combination of two direct\u2010acting antiviral drugs. Four phase 3 clinical trials (<jats:styled-content style=\"fixed-case\">ION<\/jats:styled-content>\u20101\u20134) evaluated ledipasvir\u2013sofosbuvir with and without ribavirin in patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1. High rates of sustained virologic response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) occurred with ledipasvir\u2013sofosbuvir alone in treatment\u2010na\u00efve and treatment\u2010experienced patients without cirrhosis as well as in treatment\u2010na\u00efve patients with cirrhosis when administered for 12 weeks. In treatment\u2010experienced patients with cirrhosis, 24 weeks of ledipasvir\u2013sofosbuvir was also highly effective. Furthermore, treatment\u2010na\u00efve patients without cirrhosis (particularly those with <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> serum concentrations &lt; 6 million <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/ml) can achieve a similar <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> with only 8 weeks of therapy. Similarly, in patients coinfected with human immunodeficiency virus and <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1 who were treated with ledipasvir\u2013sofosbuvir for 12 weeks, a high <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> was observed in those with and without cirrhosis as well as treatment\u2010na\u00efve and treatment\u2010experienced patients. Ledipasvir\u2013sofosbuvir is well tolerated, with fatigue, headache, nausea, diarrhea, and insomnia being the most common adverse effects, which are typically mild to moderate in nature. This combination antiviral can be taken with or without food. Key factors to consider when prescribing ledipasvir\u2013sofosbuvir are drug interactions including those mediated by the P\u2010glycoprotein transporter and increased <jats:styled-content style=\"fixed-case\">pH<\/jats:styled-content>, cost of the drug or insurance coverage, comorbid conditions, and patient and provider preferences. Postmarketing experience and ongoing clinical trials will further define the safety and role of ledipasvir\u2013sofosbuvir in the treatment of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1.<\/jats:p>","DOI":"10.1002\/phar.1748","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T19:29:40Z","timestamp":1459366180000},"page":"562-574","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ledipasvir\u2013Sofosbuvir: A Once\u2010Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection"],"prefix":"10.1002","volume":"36","author":[{"given":"Christopher M.","family":"Jensen","sequence":"first","affiliation":[{"name":"UConn School of Pharmacy Storrs Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Holle","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice UConn School of Pharmacy Storrs Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23399"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.223-235.2000"},{"key":"e_1_2_12_4_1","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America.Recommendations for Testing Managing and Treating Hepatitis C. Available fromhttp:\/\/www.hcvguidelines.org\/full-report-view. Accessed December 30 2015."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.009"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.48"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.051"},{"key":"e_1_2_12_17_1","unstructured":"Gilead Sciences Inc.Sovaldi (sofosbuvir) package insert.Foster City CA;2015"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_12_19_1","unstructured":"Gilead Sciences Inc.Harvoni (ledipasvir and sofosbuvir) package insert.Foster City CA;2015"},{"key":"e_1_2_12_20_1","unstructured":"Janssen Products LP.Olysio (simeprevir) package insert.Titusville NJ;2015"},{"key":"e_1_2_12_21_1","unstructured":"AbbVie Inc.Viekira Pak (ombitasvir\/paritaprevir\/ritonavir dasabuvir) package insert.North Chicago IL;2014"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399-10"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401499g"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000032"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.5.3007-3019.2003"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000035"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00328-07"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2011.036.09.1641618"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.030"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00215-11"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-12"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","unstructured":"LawitzE FlammS YangJC et al.Retreatment of patients who failed 8 or 12 week so f ledipasvir\/sofosbuvir\u2010based regimens with ledipasvir\/sofosbuvir for 24 weeks. Presented at The International Liver Congress 2015 \u2013 50th Annual Meeting of the European Association for the Study of Liver; Vienna Austria; April 22\u201326 2015. Available fromhttp:\/\/natap.org\/2015\/EASL\/EASL_26.htm. Accessed August 31 2015.","DOI":"10.1016\/S0168-8278(15)30012-X"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"e_1_2_12_41_1","unstructured":"GaneEJ HylandRH AnD et al.Ledipasvir\/sofosbuvir fixed\u2010dose combination is safe and effective in difficult\u2010to treat populations including GT 3 patients decompensated GT 1 patients and GT1 patients with prior sofosbuvir experience. Presented at The International Liver Congress 2014 \u2013 49th Annual Meeting of the European Association for the Study of Liver; London United Kingdom; April 9\u201313 2014. Available fromhttp:\/\/natap.org\/2014\/EASL\/EASL_23.htm. Accessed August 31 2015."},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"e_1_2_12_43_1","unstructured":"MannsM FornsX SamuelD et al.Ledipasvir\/sofosbuvir with ribavirin is safe and efficacious in decompensated and post\u2010liver transplantation patients with HCV infection: preliminary results of the SOLAR\u20102 trial. Presented at The International Liver Congress 2015 \u2013 50th Annual Meeting of the European Association for the Study of Liver; Vienna Austria; April 22\u201326 2015. Available fromhttp:\/\/natap.org\/2015\/EASL\/EASL_27.htm. Accessed August 31 2015."},{"key":"e_1_2_12_44_1","unstructured":"SamuelD MannsM FornsX et al.Ledipasvir\/sofosbuvir with ribavirin is safe in >600 decompensated and post\u2010liver transplantation patients with HCV infection: an integrated safety analysis of the SOLAR\u20101 and SOLAR\u20102 trials. Presented at The International Liver Congress 2015 \u2013 50th Annual Meeting of the European Association for the Study of Liver; Vienna Austria; April 22\u201026 2015. Available fromhttp:\/\/natap.org\/2015\/EASL\/EASL_88.htm. Accessed August 31 2015."},{"key":"e_1_2_12_45_1","unstructured":"Genentech USA Inc.Copegus (ribavirin) package insert.South San Francisco CA;2011"},{"key":"e_1_2_12_46_1","unstructured":"GermanP PangPS FangL et al.Drug\u2010Drug interaction profile of the fixed\u2010dose combination tablet ledipasvir\/sofosbuvir. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston MA; November 7\u201011 2014. Available fromhttp:\/\/www.natap.org\/2014\/AASLD\/AASLD_48.htm. Accessed August 31 2015."},{"key":"e_1_2_12_47_1","unstructured":"GermanP YangJ WestS et al.Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir\/sofosbuvir fixed\u2010dose combination tablet. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC; 2014 May. Available fromhttp:\/\/www.natap.org\/2014\/Pharm\/Pharm_04.htm. Accessed August 31 2015."},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.346"},{"key":"e_1_2_12_49_1","unstructured":"Red Book Online 2014 Truven Health Analytics Ann Arbor MI"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1748","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:16:07Z","timestamp":1761059767000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/phar.1748"],"URL":"https:\/\/doi.org\/10.1002\/phar.1748","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"2016-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}